A phase II, open-label study to assess safety and clinical utility of 68Ga-THP-PSMA PET/CT in patients with high-risk primary prostate cancer or biochemical recurrence after radical treatment

Conclusions: 68Ga-THP-PSMA PET/CT had a major clinical impact in patients with prostate cancer. Management plans changed in nearly one third of patients with primary untreated prostate cancer and in over half of patients with biochemical recurrence. These results are comparable with management change figures reported with other types of PSMA PET tracers. 68Ga-THP-PSMA was well tolerated. No patients experienced SAEs or discontinued the study due to AEs. These results together with the simple cold kit manufacturing process of 68Ga-THP-PSMA are promising for larger scale accessibility and serve as a basis for a multicentre phase III study evaluation.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Afaq, A., Payne, H., Davda, R., Hines, J., Cook, G., Meagher, M., Priftakis, D., Warbey, V., Kelkar, A., Orczyk, C., Anita, M., Needleman, S., Ferris, M., Mullen, G., Bomanji, J. Tags: GU - PSMA PET (Poster Session) Source Type: research